Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatosteatosis and insulin resistance

Archives of Medical Research

Volumn 44, Issue 4, 2013, Pages 273-280

  Ozcelik, Fatih ^a   Yuksel, Celalettin ^b   Arslan, Erol ^c   Genc, Sema ^d   Omer, Beyhan ^d   Serdar, Muhittin A ^c  

^a Erzincan Military Hospital   (Turkey)

^b Gumussuyu Military Hospital   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Adiponectin; Insulin resistance; Nonalcoholic fatty liver disease; Obesity; Triiodothyronine

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIOTHYRONINE; THYROID HORMONE; THYROXINE; TRIACYLGLYCEROL;

ABDOMINAL SUBCUTANEOUS FAT; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PROTEIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADIPOSE TISSUE; ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FATTY LIVER; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; SUBCUTANEOUS FAT, ABDOMINAL; THYROID HORMONES; WAIST CIRCUMFERENCE;

EID: 84879707834     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.04.001     Document Type: Article

References (48)

1. Youssef W.I., McCullough A.J. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol 2002, 16:733-747.
2. Lomonaco R., Ortiz-Lopez C., Orsak B., et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:1389-1397.
3. Pihlajamäki J., Boes T., Kim E.Y., et al. Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab 2009, 94:3521-3529.
4. Petersen K.F., Dufour S., Befroy D., et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2diabetes. N Engl J Med 2004, 350:664-671.
5. Crunkhorn S., Patti M.E. Links between thyroid hormone action, oxidative metabolism, and diabetes risk?. Thyroid 2008, 18:227-237.
6. Cable E.E., Finn P.D., Stebbins J.W., et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009, 49:407-417.
7. Parekh S., Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132:2191-2207.
8. Adams L.A., Feldstein A., Lindor K.D., et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004, 39:909-914.
9. Cavalieri R.R. The effects of nonthyroid disease and drugs on thyroid function tests. Med Clin North Am 1991, 75:27-39.
10. Anderson P., Cremona A., Paton A., et al. The risk of alcohol. Addiction 1993, 88:1493-1508.
11. Dixon A.K. Abdominal fat assessed by computed tomography: sex difference in distribution. Clin Radiol 1983, 34:189-191.
12. Borkan G.A., Gerzof S.G., Robbins A.H., et al. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982, 36:172-177.
13. Brunn J., Block U., Ruf G., et al. [Volumetric analysis of thyroid lobes by real-time ultrasound (author's translation)]. Dtsch Med Wochenschr 1981, 106:1338-1340.
14. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
15. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
16. Esteghamati A., Ashraf H., Khalilzadeh O., et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab (Lond) 2010, 7:26.
17. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new wordwide definition. Lancet 2005, 366:1059-1062.
18. Kuzuya T., Nakagawa S., Satoh J., et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetes Res Clin Pract 2002, 55:65-85.
19. Lee J.H., Rhee P.L., Lee J.K. Role of hyperinsulinemia and glucose intolerance in pathogenesis of nonalcoholic fatty liver patients with normal body weight. Korean J Intern Med 1998, 13:12-14.
20. Jakobsen M.U., Berentzen T., Sorensen T.I., et al. Abdominal obesity and fatty liver. Epidemiol Rev 2007, 29:77-87.
21. Utzschneider K.M., Kahn S.E. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006, 91:4753-4761.
22. Howard B.V. Insulin resistance and lipid metabolism. Am J Cardiol 1999, 84:28J-32J.
23. Cazanave S.C., Gores G.J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol 2010, 5:71-85.
24. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
25. Kendall D.M., Harmel A.P. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care 2002, 8:S635-S653.
26. Willner I.R., Waters B., Patil S.R., et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease. Am J Gastroenterol 2001, 96:2813-2814.
27. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
28. Garrow J.S., Webster J. Quetelet's index (W/H2) as a measure of fatness. Int J Obes 1985, 9:147-153.
29. Smalley K.J., Knerr A.N., Kendrick Z.V., et al. Reassessment of body mass indices. Am J Clin Nutr 1990, 52:405-408.
30. Rheeder P., Stolk R.P., Veenhouwer J.F., et al. The metabolic syndrome in black hypertensive women-waist circumference more strongly related than body mass index. S Afr Med J 2002, 92:637-641.
31. Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996, 20:291-302.
32. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000, 21:697-738.
33. Daniel S., Ben-Menachem T., Vasudevan G., et al. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999, 94:3010-3014.
34. Fulop T., Tessier D., Carpentier A. The metabolic syndrome. Pathologie Biologie 2006, 54:375-386.
35. Kotronen A., Seppälä-Lindroos A., Bergholm R., et al. Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia 2008, 51:130-138.
36. Díez J.J., Iglesias P. The role of the novel adipocyte-derived homone in human disease. Eur J Endocrinol 2003, 148:293-300.
37. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271:10697-10703.
38. Li S., Shin H.J., Ding E.L., et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179-188.
39. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
40. Yaturu S., Prado S., Grimes S.R. Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J Cell Biochem 2004, 93:491-496.
41. Evans B.A., Papaioannou M., Anastasopoulos F., et al. Differential regulation of beta3-adrenoceptors in gut and adipose tissue of genetically obese (ob/ob) C57BL/6J-mice. Br J Pharmacol 1998, 124:763-771.
42. Iacobellis G., Ribaudo M.C., Zappaterreno A., et al. Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. Clin Endocrinol (Oxf) 2005, 62:487-491.
43. Dumont J.E., Lamy F., Roger P., et al. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992, 72:667-697.
44. Marckmann P., Toubro S., Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998, 52:329-333.
45. Ditschuneit H.H., Flechtner-Mors M., Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res 1995, 3:43-48.
46. Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, invivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
47. Banks R.E., Forbes M.A., Storr M., et al. The acute phase protein in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995, 102:217-223.
48. Yudkin J.S., Kumari M., Humphries S.E., et al. Inflammation, obesity,stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 2000, 148:209-214.